Research Analysts Offer Predictions for TEVA FY2025 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Zacks Research increased their FY2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research note issued on Thursday, April 3rd. Zacks Research analyst R. Department now forecasts that the company will earn $2.48 per share for the year, up from their previous forecast of $2.42. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2025 earnings at $0.69 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.80 EPS, Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $2.62 EPS and FY2027 earnings at $2.82 EPS.

Several other research firms have also recently weighed in on TEVA. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday, April 4th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Finally, Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 2.9 %

TEVA opened at $13.54 on Monday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries has a one year low of $12.51 and a one year high of $22.80. The firm has a market capitalization of $15.35 billion, a P/E ratio of -9.33, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The company has a fifty day moving average price of $16.10 and a 200-day moving average price of $17.93.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%.

Institutional Trading of Teva Pharmaceutical Industries

A number of large investors have recently made changes to their positions in TEVA. Diversify Advisory Services LLC boosted its position in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after buying an additional 496 shares during the period. Sanctuary Advisors LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after purchasing an additional 664 shares during the period. Thrivent Financial for Lutherans grew its stake in Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock worth $4,964,000 after purchasing an additional 699 shares in the last quarter. Townsquare Capital LLC increased its holdings in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock worth $885,000 after purchasing an additional 812 shares during the period. Finally, Metis Global Partners LLC raised its position in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after purchasing an additional 860 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.